This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McIntosh, G. G. Articles by Milton, I. D. Search for Related Content PubMed PubMed Citation Articles by McIntosh, G. G. Articles by Milton, I. D.

(American Journal of Pathology. 1999;154:77-82.)
© 1999 American Society for Investigative Pathology

Technical Advances

NCL-CD10–270: A New Monoclonal Antibody Recognizing CD10 in Paraffin-Embedded Tissue

Gary G. McIntosh* , Andrew J. Lodge , Peter Watson , Andrew G. Hall , Katrina Wood , John J. Anderson , Brian Angus , Charles H. W. Horne* and Ian D. Milton*

From Novocastra Laboratories Ltd.* and Departments of Pathology and Paediatric Oncology, University of Newcastle, Newcastle-upon-Tyne, United Kingdom

CD10 (CALLA) antigen is expressed in a wide variety of epithelial and nonepithelial tissues, but its most significant application is in the diagnosis and classification of certain types of malignant lymphoma and leukemia. CD10 is expressed in a high percentage of cases of acute lymphoblastic leukemia (ALL), follicular lymphoma, Burkitt's lymphoma, and some hematopoietic tumors. Although the antigen is not lineage specific, CD10 expression is widely used to define subgroups within B-ALL and is a useful tool for detecting the presence of leukemic blasts in the bloodstream. Currently available monoclonal antibodies to CD10 have been found to be effective only in fresh-frozen tissue and for techniques such as flow cytometry. We have used a recombinant protein corresponding to the whole of CD10 to generate a monoclonal antibody that is effective in paraffin-embedded tissue sections. We have used this antibody to assay for the presence of CD10 on a range of normal and pathological tissues. Strong staining was seen in lymphoid germinal centers, renal tubules, glomeruli, syncytiotrophoblast, hepatic parenchymal canaliculi, B-lineage ALL, follicle center cell lymphoma, and a proportion of cases of large-B-cell lymphoma. We believe that this antibody will be of value in the characterization of malignant lymphoma, in particular the differential diagnosis of small-B-cell lymphoma and subtyping of lymphoblastic leukemia, as well as the investigation of the significance of expression of CD10 in other normal and pathological tissues.

This article has been cited by other articles:

				W.-B. Huang, X.-J. Zhou, J.-Y. Chen, L.-H. Zhang, K. Meng, H.-H. Ma, and Z.-F. Lu CD10-positive Stromal Cells in Gastric Carcinoma: Correlation with Invasion and Metastasis Jpn. J. Clin. Oncol., May 1, 2005; 35(5): 245 - 250. [Abstract] [Full Text] [PDF]

				C. Pan, P. M. Cardarelli, M. H. Nieder, L. B. Pickford, S. Gangwar, D. J. King, G. T. Yarranton, D. Buckman, W. Roscoe, F. Zhou, et al. CD10 Is a Key Enzyme Involved in the Activation of Tumor-activated Peptide Prodrug CPI-0004Na and Novel Analogues: Implications for the Design of Novel Peptide Prodrugs for the Therapy of CD10+ Tumors Cancer Res., September 1, 2003; 63(17): 5526 - 5531. [Abstract] [Full Text] [PDF]

				S.-Y. Xiao, H. L. Wang, J. Hart, D. Fleming, and M. R. Beard cDNA Arrays and Immunohistochemistry Identification of CD10/CALLA Expression in Hepatocellular Carcinoma Am. J. Pathol., October 1, 2001; 159(4): 1415 - 1421. [Abstract] [Full Text]